Developing your new medicine in Japan faster

High reimbursement rates for innovative drugs. A sophisticated healthcare system with universal coverage and access to medicines like CAR-T. And a new government initiative prioritizing biotech as a key component of national policy makes Japan one of the most attractive places for drug developers to discover and market new products. Endpoints News founder Arsalan Arif sits down with Tadayuki Mizutani, the pharma head at Japan’s Ministry of Health, Labor and Welfare, to discuss the market opportunity. This session is for all biotech entrepreneurs, VCs, and pharma leaders.

The Japanese Pharmaceutical Market is the third largest single market in the world after the US and China. With a large aging population, the Japanese market is expected to grow rapidly over the coming years as patients demand the latest and most effective treatments. Join senior executives from Nxera Pharma to discuss the need for an innovative new partnering model to successfully navigate Japan's clinical development, regulatory and commercial environment. Learn about how the market is evolving to encourage growth and improve patients’ access to new medicines.

Join us for a panel discussion on Japan's evolving clinical trial landscape and its potential for global pharma and biotech companies. As the world's third-largest pharmaceutical market, Japan offers a clinical development environment comparable to the US and Europe. Recent data shows Japan’s PMDA New Active Substance median approval time is faster than the US FDA, with clinical trial start-up times of around 5 months, similar to Australia, Korea and Taiwan.

Experts from leading clinical sites in Japan, global sponsors and CMIC Group will share insights and real-life examples of patient recruitment, site selection, clinical trial execution and regulatory navigation in Japan. Don’t miss this opportunity to learn how your company can successfully tap into the Japanese market and accelerate drug development.

"Japan takes longer than Western countries in the approval process." "Japanese pharmaceutical regulations greatly differ from those in the West." There are misconceptions about lengthy approval times and divergent regulations have kept many from exploring Japan's pharmaceutical market. In reality, Japan is making it easier to develop innovative foreign drugs. This presents a significant opportunity to expand your reach, deliver life-changing treatments to more patients and enhance your company's profitability. Let's talk about the latest pharmaceutical regulations with top leaders from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).

To view and download slides from this session, click here.